Those suffering from Extragonadal Germ Cell Tumors can expect a good outcome if the correct diagnostic tests are performed. There are several treatment options available to patients suffering from this form of cancer, including chemotherapy and radiation therapy. There are also clinical trials underway to further understand the disease and find cures for patients.
Symptoms of extragonadal germ cell tumors include back and breathing problems. They may also appear as symptoms of other medical problems, such as coughing and vaginal bleeding. X-rays, ultrasounds, and bone scans are used to determine the location and size of the tumor. Blood tests can also check the amount of hormones and proteins in the blood. In some cases, chemotherapy is used to treat the tumors.
Extragonadal germ cell tumors can be either benign or malignant. They can form anywhere in the body, including the brain and chest. Symptoms vary depending on the type of tumor and where it is located. The age and gender of the patient can also affect the risk of the tumor. In boys, the tumor is more likely to occur in the undescended testes.
The first step is to take a medical history and perform a physical exam to check for lumps or abnormalities in the testes. X-rays can be used to form images of the testes, ovaries, and abdomen. They are also used to detect a tumor’s location.
Blood tests can also check the number of hormones, proteins, and enzymes in the blood. They also can help determine the health of the organs. The levels of AFP and hCG can be used to help diagnose germ cell tumors. If the tumor is malignant, the levels of these proteins are high, and treatment may be necessary. If the tumor is benign, the levels of AFP and hCG may be normal.
A pathologist examines the tissue sample and may perform a biopsy to determine the presence and location of the tumor. A pathologist also performs a review of the laboratory results. The biopsy can also indicate whether the tumor is cancerous.
In addition to diagnostic tests, patients may be enrolled in clinical trials to learn more about new cancer treatments. Patients can find these trials by using PDQ, the service of the National Cancer Institute (NCI). These trials are a part of cancer research. Patients can also search by type of cancer.
Treatment of extragonadal germ cell tumors depends on the size, location, and type of tumor. Treatment can be modified depending on the tumor’s stage, as well as the gender and age of the patient.
Depending on the patient’s age, gender, location of the tumor, and other factors, there are a variety of treatment options for extragonadal germ cell tumors. Treatment can include chemotherapy, biological therapy, and surgery. It is important to understand all of the options and work with your doctor to choose a treatment that is right for you.
Extragonadal germ cell tumors are rare, and doctors don’t know why they occur. However, they can be associated with Klinefelter syndrome, which increases the risk for these tumors. Symptoms may include breathing problems, trouble with movement, and chest pain.
These tumors are usually found in the midline regions of the body, in the lungs, and in the testes. Some extragonadal germ cell tumors spread to the lymph nodes or lymph vessels. Some have the potential to spread to other parts of the body, and some can affect both the mother and baby.
Patients with extragonadal germ cell tumors may benefit from participating in clinical trials, which are research studies that test new treatments for cancer. These trials can be performed before or after cancer treatment. You can learn more about clinical trials by visiting the National Cancer Institute’s (NCI) website. If you are interested in participating in a clinical trial, ask your doctor. You can find out what types of clinical trials are open to you, and how to sign up.
The National Institutes of Health (NIH) is a federal government agency that conducts research into biomedical issues. The NIH also supports clinical trials. The NCI website lists information about clinical trials, including information about the types of trials that are available. Alternatively, you can search by trial location, drug name, or treatment type.
For patients who have a residual tumor after chemotherapy, new approaches are being tested. For example, some clinical trials use salvage chemotherapy regimens that include autologous bone marrow transplantation. This treatment option may have fewer side effects and could lead to long-term disease-free survival.
The Malignant Germ Cell International Collaborative is a group of pediatric oncologists and other experts who are concerned with the rare incidence of germ cell tumors in children. The MGCI has a mission to improve the treatment of children with germ cell tumors. It is led by A. Lindsay Frazier, MD.
Various studies are underway to understand and build a better understanding of extragonadal germ cell tumors (EGCT). The NCI (National Cancer Institute) supports clinical trials and other research efforts for the treatment of extragonadal germ cell tumors. EGCTs are usually benign, but some patients can develop secondary cancer later in life.
The treatment for extragonadal germ cell tumors depends on the type of tumor and the location of the body. Some patients may need chemotherapy or surgery. The treatment options may also be altered depending on gender and tumor stage.
EGCTs can be diagnosed using blood tests. There are three tumor markers that can help in detecting an extragonadal germ cell tumor. These are alpha-fetoprotein (AFP), cytokeratins, and luteinizing hormone (LH).
In some centers, carboplatin is used as the standard of care. Treatment may include surgery, chemotherapy, and immunotherapy.
EGCTs are rare in children, but they are more common in adolescents and adults. Male extragonadal germ cell tumors are more aggressive than female tumors. They usually cause symptoms, such as breathing problems, chest pain, and trouble with movement. In addition to chemotherapy, patients may be given radiation therapy, which is a powerful beam of energy.
EGCTs are classified into three subgroups. There are seminomas, nonseminomas and teratomas. EGCTs can be treated according to the International Germ Cell Consensus Classification (IGC) system. These groups are based on the expected response to treatment.
For patients with an intermediate or poor prognosis, treatment includes three cycles of bleomycin-etoposide-cisplatin (BEP) followed by four cycles. The median duration of follow-up is approximately 5 years.
For patients with an advanced or metastatic germ cell tumor, pembrolizumab is available. This treatment is safe and well tolerated. However, it has limited antitumor activity.
The NCI is also involved in clinical trials that test combinations of drugs. The purpose of these studies is to identify effective combination regimens. The clinical trials also look for ways to prevent or detect extragonadal germ cell tumors.
The Malignant Germ Cell International Collaborative is a group of specialists that provides evidence-based approaches to the management of GCTs across age groups.
Typically, extragonadal germ cell tumors develop from embryonic or sperm cells, but they may also form from cells that travel to other parts of the body. These tumors are rare and have a wide differential diagnosis. They can be benign or malignant.
Most extragonadal germ cell tumors occur in areas other than the ovaries and testes. The most common sites are the retroperitoneum, the mediastinum, and the pineal region. The incidence is higher in women than in men.
The National Cancer Institute (NCI) is a part of the National Institutes of Health (NIH) and provides general information about germ cell tumors. It also provides links to clinical trials. These trials are meant to improve treatments for germ cell tumors. You can search by type of cancer, age, location, or type of treatment.
These tumors are characterized by unique behavior and molecular characteristics. The International Germ Cell Consensus Classification is a prognostic factor-based staging system for metastatic germ cell cancers. It divides extragonadal germ cell tumors into non-seminomatous and seminomatous categories. Non-seminomatous extragonadal germ cell tumors have poorer prognoses than mediastinal EGCTs.
Extragonadal germ cell tumors are usually diagnosed using imaging tests. They may begin in the mediastinum, the pineal gland, or the ovaries. Tests may include blood tests to see if cancer cells have spread to other parts of the body. Tests may also be performed to see if there are lumps or swellings in the testicles. If cancer is found, tests may be performed to see if cancer has recurred.
The incidence of extragonadal germ cell tumors is higher in women than in men. Some of these tumors have been associated with autoimmune hemolytic anemia. Other symptoms may include chest pain and breathing problems.
The National Cancer Institute (NCI) has a service called PDQ (Patient-Centered Drug Queries) that provides current information about extragonadal germ cell tumors. This information is based on a review of the medical literature and is not a policy statement of the NCI.
The PDQ summaries are not meant to be comprehensive. You may need to visit the NCI website to find current information on extragonadal germ cell tumors.
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
U.S. National Library of Medicine. (n.d.). https://www.ncbi.nlm.nih.gov/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/